Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2017 | Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses | Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG ; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C. | Journal of Clinical Oncology | 134 | 115 | |
2017 | Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer) | Nokihara H; Lu S; Mok T.S.K; Nakagawa K; Yamamoto N; Shi Y.K; Zhang L; Soo R.A; CHIH-HSIN YANG ; Sugawara S; Nishio M; Takahashi T; Goto K; Chang J; Maemondo M; Ichinose Y; Cheng Y; Lim W.T; Morita S; Tamura T. | Annals of Oncology | 75 | 68 | |
2016 | A randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in asian patients with advanced stage pulmonary adenocarcinoma | Mok T.S.K; Geater S.L; Su W.-C; Tan E.-H; CHIH-HSIN YANG ; Chang G.-C; Han M; Komarnitsky P; Payumo F; Garrus J.E; Close S; Park K. | Journal of Thoracic Oncology | 44 | 41 | |
2013 | Symptom control and quality of life in lux-lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations | CHIH-HSIN YANG ; Hirsh V; Schuler M; Yamamoto N; O'Byrne K.J; Mok T.S.K; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist L.V. | Journal of Clinical Oncology | 295 | 242 | |
2013 | Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study | Wu Y.-L; Fukuoka M; Mok T.S.K; Saijo N; Thongprasert S; CHIH-HSIN YANG ; Chu D.-T; Rukazenkov Y. | Lung Cancer | 41 | 39 |